The TAD structural changes involve the vascular endothelial growth factor gene VEGFA, which is a major tumor angiogenic gene that is over-expressed in leukemia (see reviews43,44 for more details), consistent with the fact that K562 cells are chronic myelogenous leukemia cells. This evidence concerns the gene VEGFA and neoplasm.